

CLAIMS

1. A composition containing a GLP-1 compound which composition is a gel.
- 5 2. A composition, according to Claim 1, which composition has thixotropic properties.
3. Composition, according to Claim 1 or 2, containing not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of a GLP-1 compound and, preferably, containing not more than about 100 mg/ml of a GLP-1
10 compound.
4. Composition, according to any one of the preceding claims, containing a phenolic or an alcoholic aromatic compound.
- 15 5. Composition, according to the preceding claim, wherein the phenolic or alcoholic aromatic compound is a pharmaceutically acceptable antimicrobial preservative.
6. Composition, according to the preceding claim, wherein the pharmaceutically acceptable antimicrobial preservative is benzyl alcohol, a cresol, e.g., m-cresol, a phenol, e.g.,
20 phenol or resorcinol, or a paraben, e.g., methyl paraben or propyl paraben.
7. Composition, according to any one of the preceding claims, wherein the thixotropic property only or mainly results from the presence of a GLP-1 compound.
- 25 8. Composition, according to anyone of the preceding claims, wherein the thixotropic property only or mainly results from the presence of a GLP-1 compound together with a pharmaceutically acceptable antimicrobial preservative.
9. Composition, according to anyone of the preceding claims, containing divalent metal
30 ions, e.g. zinc, calcium, magnesium or cobalto ions.
10. Composition, according to the preceding claim, wherein the metal ions are zinc ions.
11. Composition, according to anyone of the preceding claims, containing 1 zinc ion per
35 molecule of the GLP-1 compound or less and, preferably, they contain less than 0.4 zinc ion per molecule of the GLP-1 compound, more preferred they contain between 0.4 and 0.1 zinc

ion per molecule of the GLP-1 compound and most preferred between 0.2 and above 0.1 zinc ion per molecule of the GLP-1 compound.

12. A method for the treatment of diabetes mellitus in a mammal in need of such
5 treatment comprising the administration of a composition according to any one of the preceding claims containing an effective amount of the GLP-1 compound.

13. A method, according to the preceding claim, wherein the administration is performed
10 by subcutaneous injection.

14. Any novel feature or combination of features described herein.

1995-12-20, ToN/KGF, IL

Novo Nordisk A/S
4343-WO, ToN

15